Información del artículo
La prevalencia de la infección por el virus de la hepatitis C (VHC) en las prisiones españolas es muy elevada (38,5%). Las características de los pacientes infectados, especialmente la elevada coinfección con el virus de la inmunodeficiencia humana (VIH), hacen probable que la morbilidad y mortalidad producida por enfermedad hepática grave secundaria a esta infección aumente de forma considerable en los próximos años. Un grupo de expertos multidisciplinar con experiencia con pacientes internados en prisiones españolas ha sido invitado a establecer una serie de recomendaciones para el diagnóstico y tratamiento de la hepatitis C en las prisiones españolas.
Palabras clave:
Hepatitis C
Reclusos
Prisiones
Infección por VIH
The prevalence of HCV infection in Spanish prisons is very high (38.5%). The characteristics of the infected patients, particularly the high rate of HIV coinfection, makes it very likely that the morbidity and mortality produced by serious liver disease secondary to this infection will increase considerably in the coming years. A group of Spanish experts with experience in patients who are inmates has been invited to establish a series of recommendations for the diagnosis and treatment of chronic hepatitis C infection in Spanish prisons.
Key words:
Hepatitis C
Inmates
Prisons
HIV infection
El Texto completo está disponible en PDF
Bibliografía
[1.]
Grupo del Noroeste para el estudio de la hepatitis por virus C en el medio penitenciario.
Seroprevalencia de infección por virus C de la hepatitis en población reclusa del noroeste de España a su ingreso en prisión.
Rev Esp Salud Pública, 72 (1998), pp. 43-51
[2.]
C. Añón, J.A. Del Olmo, F. Llovet, M.A. Serra, S. Gilabert, F. Rodríguez, et al.
Virus C de la hepatitis entre población penitenciaria de Valencia.
Rev Esp Enferm Dig, 87 (1995), pp. 505-508
[3.]
F. Pérez-Agudo, F.J. Alonso Moreno, J. Urbina Torija.
Prevalencia de infección por el virus de la inmunodeficiencia humana tipo 1 y de Mycobacterium tuberculosis en una población reclusa entre los años 1989 y 1995.
Med Clin (Barc), 110 (1998), pp. 167-170
[4.]
P. Saiz de la Hoya, M. Bedia, J. Murcia, J. Cebriá, J. Sánchez-Payá, J. Portilla.
Factores predictivos de infección por el VIH, VHC y coinfección en la población reclusa de una prisión española.
Enferm Infecc Microbiol Clin, 23 (2005), pp. 53-57
[5.]
J.R. Pallás, C. Farinas-Álvarez, D. Prieto, M. Delgado-Rodríguez.
Coinfections by HIV, hepatitis B and hepatitis C in imprisoned injecting drug users.
Eur J Epidemiol, 15 (1999), pp. 699-704
[6.]
M.G. Peters, N.A. Terrault.
Alcohol use and hepatitis C.
Hepatology, 36 (2002), pp. S220-S225
[7.]
J. Portilla, J. Esteban, R. Llinares, J. Belda, J. Sánchez-Payá, M.I Manso, grupo de estudio protocolo INH.
Prevalencia de infecciones crónicas ocultas en una cohorte de pacientes en tratamiento sustitutivo con metadona.
Med Clin (Barc), 116 (2001), pp. 330-332
[8.]
B.R. Edlin.
Prevention and treatment of hepatitis C in injection drug users.
Hepatology, 36 (2002), pp. 210-219
[9.]
National Institutes of Health Consensus Statement on Management of Hepatitis C: 2002. Gastroenterology. 2002;123:2082-99.
[10.]
P. Saiz de la Hoya, E. Ortega, Grupo de Trabajo SESP/GESIDA sobre protocolos de coordinación.
Protocolos de Coordinación entre Servicios Sanitarios Penitenciarios y Hospitales de Referencia.
SCM, (2004),
[11.]
A. Marco, A. Lonca, A. Laliga.
Estrategias para el manejo de la infección por el virus de la hepatitis C.
Rev Esp Sanid Penit, 4 (2002), pp. 58-69
[12.]
R.G. Knodell, K.G. Ishak, W.C. Black, T.S. Chen, R. Craig, N. Kaplowitz, et al.
Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis.
Hepatology, 1 (1981), pp. 431-435
[13.]
M. Wawrzynowicz-Syczewska, J. Kubicka, Z. Lewandowski, A. Boron-Kaczmarska, M. Radkowski.
Natural history of acute symptomatic hepatitis type C.
Infection, 32 (2004), pp. 138-143
[14.]
X. Forns, S. Ampurdanés, J.M. Llovet, J. Aponte, L. Quinto, E. Martínez-Bauer, et al.
Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model.
Hepatology, 36 (2002), pp. 986-992
[15.]
Y. Benhamou, M. Bochet, V. Di Martino, F. Charlotte, F. Azria, A. Coutellier, et al.
Liver fibrosis progression in HIV and hepatitis C virus coinfected patients. The Multivrc Group.
Hepatology, 30 (1999), pp. 1054-1058
[16.]
C. Martínez-Sierra, A. Arizcorreta, F. Díaz, R. Roldán, L. Martín-Herrera, E. Pérez-Guzmán, et al.
Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients coinfected with hepatitis C virus and human immunodeficiency virus.
Clin Infect Dis, 36 (2003), pp. 491-498
[17.]
J.B. Wong, W.G. Bennett, R.S. Koff, S.G. Pauker.
Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs.
JAMA, 280 (1998), pp. 2088-2093
[18.]
G. Spinzi, G. Minoli.
To biopsy or not to biopsy.
Hepatology, 34 (2001), pp. 438
[19.]
A. Andriulli, A. Mangia, G. Niro, E. Caturelli.
To biopsy or not to biopsy.
Hepatology, 34 (2001), pp. 438
[20.]
J.L. Dienstag.
The role of liver biopsy in chronic hepatitis C.
Hepatology, 36 (2002), pp. 152-160
[21.]
A. Sud, J.M. Hui, G.C. Farrell, P. Bandara, J.G. Kench, C. Fung, et al.
Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance in a probability index.
Hepatology, 39 (2004), pp. 1239-1247
[22.]
F. Imbert-Bismut, V. Ratziu, L. Pieroni, F. Charlotte, Y. Benhamou, T. Poynard.
Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study.
Multivirc Group Lancet, 357 (2001), pp. 1069-1075
[23.]
R.P. Myers, M. De Torres, F. Imbert-Bismut, V. Ratziu, F. Charlotte, T. Poynard, Multivirc Group.
Biochemical markers of fibrosis in patients with chronic hepatitis C: a comparison with prothrombin time, platelet count, and age-platelet index.
Dig Dis Sci, 48 (2003), pp. 146-153
[24.]
C.T. Wai, J.K. Greenson, R.J. Fontana, J.D. Kalbfleisch, J.A. Marrero, H.S. Conjeevaram, et al.
A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C.
Hepatology, 38 (2003), pp. 518-526
[25.]
E. Rossi, L. Adams, A. Prins, M. Bulsara, B. De Boer, G. Garas, et al.
Validation of the FibroTest biochemical markers score in assessing liver fibrosis in hepatitis C patients.
Clin Chem, 49 (2003), pp. 450-454
[26.]
V. Kaul, F.K. Friedenberg, L.E. Braitman, U. Anis, N. Zaeri, J. Fazili, et al.
Development and validation of a model to diagnose cirrhosis in patients with hepatitis C.
Am J Gastroenterol, 97 (2002), pp. 2623-2628
[27.]
R.P. Myers, Y. Benhamou, F. Imbert-Bismut, V. Thibault, M. Bochet, F. Charlotte, et al.
Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients.
AIDS, 17 (2003), pp. 721-725
[28.]
W.M. Rosenberg, M. Voelker, R. Thiel, M. Becka, A. Burt, D. Schuppan, et al.
Serum markers detect the presence of liver fibrosis: A cohort study.
Gastroenterology, 127 (2004), pp. 1704-1713
[29.]
C. Puoti, R. Castellacci, F. Montagnese, S. Zaltron, G. Stornaiuolo, M. Bergami, et al.
Histological and virological features and follow-up of hepatitis C virus carriers with normal aminostransferase levels: the Italian prospective study of the asymptomatic C carriers (ISACC).
J Hepatol, 37 (2002), pp. 117-123
[30.]
B.R. Bacon.
Treatment of patients with hepatitis C and normal serum aminotransferase levels.
Hepatology, 36 (2002), pp. 79-84
[31.]
S. Zeuzem, M. Diago, E. Gane, R. Reddy, P. Pockros, D. Prati, et al.
Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels.
Gastroenterology, 127 (2004), pp. 1724-1732
[32.]
S. Boyacioglu, G. Gur, U. Yilmaz, M. Korkmaz, B. Demirhan, B. Bilezikci, et al.
Investigation of possible clinical and laboratory predictors of liver fibrosis in hemodialysis patients infected with hepatitis C virus.
Transplant Proc, 36 (2004), pp. 50-52
[33.]
A. Alberti, N. Clumeck, S. Collins, W. Gerlich, J. Lundgren, G. Palu, et al.
Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients.
J Hepatol, 5 (2005), pp. 615-624
[34.]
L. Castera, J. Vergniol, J. Foucher, B. Le Bail, E. Chanteloup, M. Haaser, et al.
Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C.
Gastroenterology, 128 (2005), pp. 343-350
[35.]
V. Soriano, M. Puoti, M. Sulkowski, S. Mauss, P. Cacoub, A. Cargnel, et al.
Care of patients with hepatitis C and HIV co-infection.
AIDS, 18 (2004), pp. 1-12
[36.]
V. Soriano, J.M. Miró, J. García-Samaniego, J. Torre-Cisneros, M. Núñez, J. Del Romero, et al.
Consensus conference on chronic viral hepatitis and HIV infection: update Spanish recommendations.
J Viral Hepat, 11 (2004), pp. 2-17
[37.]
D.B. Strader, T. Wright, D.L. Thomas, L.B. Seeff.
Diagnosis, management, and treatment of hepatitis C.
Hepatology, 39 (2004), pp. 1147-1171
[38.]
EASL, International Consensus Conference on Hepatitis C.
Consensus statement.
J Hepatol, 30 (1999), pp. 956-961
[39.]
M.P. Manns, J.G. McHutchison, S.C. Gordon, V.K. Rustgi, M. Shiffman, R. Reindollar, et al.
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial.
Lancet, 358 (2001), pp. 958-965
[40.]
M.W. Fried, M.L. Shiffman, K.R. Reddy, C. Smith, G. Marinos, F.L. Goncales Jr., et al.
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
N Engl J Med, 347 (2002), pp. 975-982
[41.]
S.J. Hadziyannis, H. Sette Jr., T.R. Morgan, V. Balan, M. Diago, P. Marcellin, et al.
Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C. A randomized study of treatment duration and ribavirin dose.
Ann Intern Med, 140 (2004), pp. 346-355
[42.]
A. Mangia, R. Santoro, N. Minerva, G.L. Ricci, V. Carreta, M. Persico, et al.
Peginterferon alpha-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3.
N Engl J Med, 352 (2005), pp. 2609-2617
[43.]
S. Zeuzem, R. Hultcrantz, M. Bourliere, T. Goeser, P. Marcellin, J.M. Sánchez-Tapias, et al.
Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3.
J Hepatol, 40 (2004), pp. 993-999
[44.]
A. Alberti, F. Noventa, L. Benvegnu, S. Boccato, A. Gatta.
Prevalence of liver disease in a population of asymptomatic persons with hepatitis C virus infection.
Ann Intern Med, 137 (2002), pp. 961-964
[45.]
D. Prati, E. Taioli, A. Zanella, E. Della Torre, S. Butelli, E. Del Vecchio, et al.
Updated definitions of healthy ranges for serum alanine aminotransferase levels.
Ann Intern Med, 137 (2002), pp. 1-10
[46.]
C.H. Kim, C.M. Nam, S.H. Jee, K.H. Han, D.K. Oh, I. Suh.
Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study.
BMJ, 328 (2004), pp. 983
[47.]
O. Takeshi, A. Makiyama, M. Nakayama, Y. Sumida, H. Mitsuyoshi, T. Nakajima, et al.
A Follow-up study to determine the value of liver biopsy an need for antiviral therapy for hepatitis c virus carriers with persistently normal serum aminotransferase.
J Hepatol, 43 (2005), pp. 599-605
[48.]
P.L. Almasio.
Weight-based dosing: which impact on efficacy and safety of therapy?.
Dig Liver Dis, 36 (2004), pp. 349-353
[49.]
G.L. Davis, J.R. Rodrigue.
Treatment of chronic hepatitis C in active drug users.
N Engl J Med, 345 (2001), pp. 215-217
[50.]
Y. Falck-Ytter, H. Kale, K.D. Mullen, S.A. Sarbah, L. Sorescu, A.J. McCullough.
Surprisingly small effect of antiviral treatment in patients with hepatitis C.
Ann Intern Med, 136 (2002), pp. 288-292
[51.]
M.D. Stein, J. Maksad, J. Clarke.
Hepatitis C disease among injection drug users: knowledge, perceived risk and willingness to receive treatment.
Drug Alcohol Depend, 61 (2001), pp. 211-215
[52.]
G. Robaeys, C. Mathei, F. Buntinx, M. Vanranst.
Management of hepatitis C virus infections in intravenous drug users.
Acta Gastroenterol Belg, 65 (2002), pp. 99-100
[53.]
S.H. Mehta, A. Cox, D.R. Hoover, X.H. Wang, W. Mao, S. Ray, et al.
Protection against persistence of hepatitis C.
Lancet, 359 (2002), pp. 1478-1483
[54.]
M. Backmund, K. Meyer, Von Zielonka., D. Eichenlaub.
Treatment of hepatitis C infection in injection drug users.
Hepatology, 34 (2001), pp. 188-193
[55.]
D.L. Sylvestre.
Treating hepatitis C in methadone maintenance patients: an interim analysis.
Drug Alcohol Depend, 67 (2002), pp. 117-123
[56.]
J.G. McHutchison, S.C. Gordon, E.R. Schiff, M.L. Shiffman, W.M. Lee, V.K. Rustgi, et al.
Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C.
N Engl J Med, 339 (1998), pp. 1485-1492
[57.]
T. Poynard, P. Marcellin, S.S. Lee, C. Niederau, G.S. Minuk, G. Ideo, et al.
Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus.
Lancet, 352 (1998), pp. 1426-1432
[58.]
V. Grando-Lemaire, P. Goisset, F. Sorge, J.C. Trinchet, L. Castera, D. Roulot, et al.
Prise en charge de l’infection par le virus de l’hépatite C dans une population de toxicomanes suivis dans un centre spécialisé ambulatoire. Faisabilité et résultats.
Gastroenterol Clin Biol, 26 (2002), pp. 1091-1096
[59.]
D.H. Van Thiel, A. Anantharaju, S. Creech.
Response to treatment of hepatitis C in individuals with a recent history of intravenous drug abuse.
Am J Gastroenterol, 98 (2003), pp. 2281-2288
[60.]
M. Schaefer, F. Schmidt, C. Folwaczny, R. Lorenz, G. Martin, N. Schindlbeck, et al.
Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups.
Hepatology, 37 (2003), pp. 443-451
[61.]
S. Mauss, F. Berger, J. Goelz, B. Jacob, G. Schmutz.
A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance.
Hepatology, 40 (2004), pp. 120-124
[62.]
A. Spaulding, C. Greene, K. Davidson, M. Schneidermann, J. Rich.
Hepatitis C in state correctional facilities.
Prev Med, 28 (1999), pp. 92-100
[63.]
Saiz de la Hoya P, Viciana P, et al. CAPRI. Calidad Asistencial en Prisiones. Documento de consenso. Ed. SCM. Madrid 2002. Disponible en: http://www.sesp.es/sesp/capri/index.html
[64.]
Centers for Disease Control and Prevention. Prevention and control of infections with hepatitis viruses correctional settings. MMWR 2003;52(No. RR-1): 1-33. Disponible en: www.cdc.gov/mmwr/preview/mmwrhtml/rr5201a1.htm
[65.]
Federal Bureau of prisons clinical practice guidelines for the prevention and treatment of viral hepatitis. February 2003. Disponible en: http://www.hcvinprison.org.
[66.]
R.K. Sterling, C.M. Hofmann, V.A. Luketic, A.J. Sanyal, M.J. Contos, S.A. Mills, et al.
Treatment of chronic hepatitis C virus in the Virginia Department of Corrections: can compliance overcome racial differences to responso?.
Am J Gastroenterol, 99 (2004), pp. 866-872
[67.]
S.A. Allen, A.C. Spaulding, A.M. Osei, L.E. Taylor, A.M. Cabral, J.D. Rich.
Treatment of chronic hepatitis C in a state correctional facility.
Ann Intern Med, 138 (2003), pp. 187-190
[68.]
D. Bernstein.
Treatment of chronic hepatitis C in a state correctional facility.
Ann Intern Med, 140 (2004), pp. 50-51
[69.]
T.M. Hammett.
Adopting more systematic approaches to hepatitis C treatment in correctional facilities.
Ann Intern Med, 138 (2003), pp. 235-236
[70.]
C. Skipper, J.M. Guy, J. Parkes, P. Roderick, W.M. Rosenberg.
Evaluation of a prison outreach clinic for the diagnosis and prevention of hepatitis C: implications for the national strategy.
Gut, 52 (2003), pp. 1500-1504
[71.]
B. Soto, A. Sánchez-Quijano, L. Rodrigo, J.A. Del Olmo, M. García-Bengoechea, J. Hernández-Quero, et al.
Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis.
J Hepatol, 26 (1997), pp. 1-5
[72.]
S.C. Darby, D.W. Ewart, P.L. Giangrande, R.J. Spooner, C.R. Rizza, G.M. Dusheiko, et al.
Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. U.K Haemophilia Centre Directors’ Organisation.
Lancet, 350 (1997), pp. 1425-1431
[73.]
H.K. Monga, M.C. Rodríguez-Barradas, K. Breaux, K. Khattak, C.L. Troisi, M. Vélez, et al.
Hepatitis C infection-related morbidity and mortality among patients with human immunodeficiency virus infection.
Clin Infect Dis, 33 (2001), pp. 240-247
[74.]
I. Bica, B. McGovern, R. Dhar, D. Stone, K. McGowan, R. Scheib, et al.
Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection.
Clin Infect Dis, 32 (2001), pp. 492-497
[75.]
D. Salmon-Ceron, Ch. Lewden, P. Morlat, S. Bévilacqua, E. Jougla, F. Bonnet, et al.
Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol.
J Hepatol, 42 (2005), pp. 799-805
[76.]
N. Qurishi, C. Kreuzberg, G. Luchters, W. Effenberger, B. Kupfer, T. Sauerbruch, et al.
Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection.
Lancet, 362 (2003), pp. 1708-1713
[77.]
Y. Benhamou, V. Di Martino, M. Bochet, G. Colombet, V. Thibault, A. Liou, et al.
Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy.
Hepatology, 34 (2001), pp. 283-287
[78.]
J. Macias, V. Castellano, N. Merchante, R.B. Palacios, J.A. Mira, C. Saez, et al.
Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine.
AIDS, 18 (2004), pp. 767-774
[79.]
F.J. Torriani, M. Rodríguez-Torres, J.K. Rockstroh, E. Lissen, J. González García, A. Lazzarin, et al.
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-patients.
N Engl J Med, 351 (2004), pp. 438-450
[80.]
F. Carrat, F. Bani-Sadr, S. Pol, E. Rosenthal, F. Lunel-Fabiani, A. Benzekri, et al.
Pegylated interferon alfa-2b vs interferon alfa-2b plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.
JAMA, 292 (2004), pp. 2839-2848
[81.]
R.T. Chung, J. Andersen, P. Volberding, G.K. Robbins, T. Liu, K.E. Sherman, et al.
Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons.
N Engl J Med, 351 (2004), pp. 451-459
[82.]
M. Laguno, J. Murillas, J.L. Blanco, E. Martínez, R. Miquel, J.M. Sánchez-Tapias, et al.
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients.
AIDS, 18 (2004), pp. F27-F36
[83.]
F.J. Torriani, R.M. Ribeiro, T.L. Gilbert, U.M. Schrenk, M. Clauson, D.M. Pacheco, et al.
Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) dynamics during HCV treatment in HCV/HIV coinfection.
J Infect Dis, 188 (2003), pp. 1498-1507
[84.]
K.E. Sherman, N.J. Shire, S.D. Rouster, M.G. Peters, M. James Koziel, R.T. Chung, et al.
Viral kinetics in hepatitis C or hepatitis C/human immunodeficiency virus-infected patients.
Gastroenterology, 128 (2005), pp. 313-327
[85.]
O. Reichard, H. Glaumann, A. Fryden, G. Norkrans, R. Wejstal, O. Weiland.
Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon.
J Hepatol, 30 (1999), pp. 783-787
[86.]
A. Moreno, C. Quereda, L. Moreno, M.J. Pérez-Elías, A. Muriel, J.L. Casado, et al.
High rate of didanosine-related mitochondrial toxicity in HIV/HCV-coinfected patients receiving ribavirin.
Antivir Ther, 9 (2004), pp. 133-138
[87.]
A. Lafeuillade, G. Hittinger, S. Chapadaud.
Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection.
Lancet, 357 (2001), pp. 280-281
[88.]
S. Mauss, W. Valenti, J. DePamphilis, F. Duff, L. Cupelli, S. Passe, et al.
Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy.
AIDS, 18 (2004), pp. F21-F25
[89.]
D.L. Musselman, D.H. Lawson, J.F. Gumnick, A.K. Manatunga, S. Penna, R.S. Goodkin, et al.
Paroxetine for the prevention of depression induced by high-dose interferon alfa.
N Engl J Med, 344 (2001), pp. 961-966
[90.]
D. Zdilar, K. Franco-Bronson, N. Buchler, J.A. Locala, Z.M. Younossi.
Hepatitis C, interferon alfa, and depression.
Hepatology, 31 (2000), pp. 1207-1211
[91.]
M.W. Russo, M.W. Fried.
Side effects of therapy for chronic hepatitis C.
Gastroenterology, 124 (2003), pp. 1711-1719
[92.]
M.W. Fried.
Side effects of therapy of hepatitis C and their management.
Hepatology, 36 (2002), pp. 237-244
[93.]
J.G. McHutchison, M. Manns, K. Patel, T. Poynard, K.L. Lindsay, C. Trepo, et al.
Adherence to combination therapy enhances sustained response in genotype- 1-infected patients with chronic hepatitis C.
Gastroenterology, 123 (2002), pp. 1061-1069
Este documento cuenta con el patrocinio científico de la Asociación Española para el Estudio del Hígado (AEEH), el Grupo de Estudios sobre el Sida (GESIDA) de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC) y la Sociedad Española de Sanidad Penitenciaria (SESP). Las opiniones expresadas por los autores no reflejan necesariamente la posición del GESIDA, la AEEH o la SESP.
Copyright © 2006. Elsevier España S.L.. Todos los derechos reservados
